1. Braun, M. M. et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat. Rev. Drug Discov. 9, 519–522 (2010).
2. Westermark, K. et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat. Rev. Drug Discov. 10, 341–347 (2011).
3. Song, P., Gao, J., Inagaki, Y., Kokudo, N. & Tang, W. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis. Res. 1, 3–9 (2012).
4. [No authors listed]. Orphan Drug Act. H. R. 5238, Public Law No. 97–414, 97th Congress. National Institutes of Health
https://history.nih.gov/research/downloads/PL97-414.pdf
(1983).
5. European Commission. Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another. European Commission: Health and Consumers Directorate-General
http://ec.europa.eu/health/files/orphanmp/2014-03_guideline_rev4_final.pdf
(2014).